Portfolio Details

Virtual Incision

Current

Virtual Incision is reimagining robotically assisted surgery, with simple innovations offering mobility, flexibility and accessibility to provide minimally invasive options to more patients. The company is developing the MIRA (“miniaturized in vivo robotic assistant”) Platform, a first-of-its-kind miniaturized surgical device, focusing first on colon resection, with follow-on specialty robots for additional potential applications.

Baird Capital invests in the Technology & Services sector, including tech business services, as well as businesses that provide services directly or indirectly to the healthcare industry. Baird Capital and predecessor entities previously made investments in MedTech including investments in medical tools (e.g., DNA analysis), Medical devices (e.g., bladder control, heart valves, surgical robotics, etc.) and certain areas of Industrials and Consumer Products.

Learn more about the company

Current

Team: Venture Capital
Invested Date: November 2021
Status: Active
Location: U.S.

See All Transactions

Related Content

Virtual Incision Announces NASA Grant

Baird Capital portfolio company Virtual Incision announced that its MIRA® Platform will test its skills in space on a 2024 technology demonstration mission aboard the International Space Station.

Person handling equipment in a lab with microscopes.

Virtual Incision Announces Final Stage of FDA Approval for MIRA®

MIRA is a first-of-its-kind miniaturized surgical robotic support device, focusing first on colon resection, with follow-on specialty robots for additional potential applications.

Abstract image of multi color blocks in motion to the right.

Baird Capital Invests in Virtual Incision

The funds will be used to support regulatory and clinical programs leading to the commercialization of the company’s MIRA® (“miniaturized in vivo robotic assistant”) Surgical Platform.